IRVING, Texas, Sept. 13, 2011 (GLOBE NEWSWIRE) -- Caris Life Sciences™, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, this week at the ASCO Breast Cancer Symposium presented clinical data that demonstrates the importance of understanding individual patients' unique tumor biology and genetics in personalizing breast cancer treatments. The posters were developed from the analysis of breast cancer patient data from the Caris Target Now™ database of molecular profiles, which includes data on more than 25,000 tumors profiled since 2005 across the spectrum of cancers.
